HomeCompareDISH vs ABBV

DISH vs ABBV: Dividend Comparison 2026

DISH yields 34.66% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DISH wins by $67.9K in total portfolio value
10 years
DISH
DISH
● Live price
34.66%
Share price
$5.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$172.6K
Annual income
$25,855.68
Full DISH calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — DISH vs ABBV

📍 DISH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDISHABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DISH + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DISH pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DISH
Annual income on $10K today (after 15% tax)
$2,946.27/yr
After 10yr DRIP, annual income (after tax)
$21,977.33/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, DISH beats the other by $110.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DISH + ABBV for your $10,000?

DISH: 50%ABBV: 50%
100% ABBV50/50100% DISH
Portfolio after 10yr
$138.7K
Annual income
$25,790.70/yr
Blended yield
18.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DISH
Analyst Ratings
1
Strong
14
Buy
18
Hold
8
Sell
Consensus: Hold
Price Target
$31.36
+443.5% upside vs current
Range: $10.00 — $50.00
Altman Z
-1633.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DISH buys
0
ABBV buys
0
No recent congressional trades found for DISH or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDISHABBV
Forward yield34.66%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$172.6K$104.7K
Annual income after 10y$25,855.68$25,725.73
Total dividends collected$124.1K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$31.36$256.15

Year-by-year: DISH vs ABBV ($10,000, DRIP)

YearDISH PortfolioDISH Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,166$3,466.20$11,559$438.51+$2.6KDISH
2$19,747$4,589.06$13,494$640.86+$6.3KDISH
3$27,108$5,978.41$15,951$945.97+$11.2KDISH
4$36,675$7,669.97$19,152$1,413.89+$17.5KDISH
5$48,941$9,698.18$23,443$2,146.38+$25.5KDISH
6$64,461$12,094.95$29,391$3,321.96+$35.1KDISH
7$83,862$14,888.49$37,948$5,265.87+$45.9KDISH
8$107,835$18,102.29$50,795$8,596.74+$57.0KDISH
9$137,137$21,754.18$71,034$14,549.41+$66.1KDISH
10$172,593$25,855.68$104,715$25,725.73+$67.9KDISH

DISH vs ABBV: Complete Analysis 2026

DISHStock

DISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. The company also provides access to movies and television shows through TV or Internet-connected devices; and dishanywhere.com and mobile applications on Internet-connected devices to view authorized content, search program listings, and remotely control certain features of their DVRs. In addition, it offers Sling TV services, including Sling domestic, Sling International, Sling Latino, Sling Orange, and Sling Blue services that require an Internet connection and are available on streaming-capable devices, such as streaming media devices, TVs, tablets, computers, game consoles, and phones, as well as market SLING TV services to consumers who do not subscribe to traditional satellite and cable pay-TV services. Further, the company provides wireless subscribers consumer plans with no annual service contracts, as well as monthly service plans, including high-speed data and unlimited talk and text. As of December 31, 2021, it had 10.707 million pay-TV subscribers in the United States, including 8.221 million DISH TV subscribers and 2.486 million SLING TV subscribers. The company offers receiver systems and programming through direct sales channels, as well as independent third parties, such as small retailers, direct marketing groups, local and regional consumer electronics stores, retailers, and telecommunications companies. DISH Network Corporation was founded in 1980 and is headquartered in Englewood, Colorado.

Full DISH Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DISH vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DISH vs SCHDDISH vs JEPIDISH vs ODISH vs KODISH vs MAINDISH vs JNJDISH vs MRKDISH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.